$CRL News

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

CLSA Downgrades Charles River Laboratories International (CRL)

What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?

Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued?

Does Arovella CAR-iNKT NGS Partnership Deepen Charles River’s Cell Therapy Moat or Stretch CRL Too Thin?

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

Cell-Based Assay Services for Preclinical Use Only Global Market Report 2026 Released — Profiles Charles River, Labcorp, Eurofins and Evotec

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

Mizuho Maintains Neutral on Charles River, Raises Price Target to $230

Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $260

3 Reasons to Avoid CRL and 1 Stock to Buy Instead

Is This the Right Time to Hold CRL Stock in Your Portfolio?

Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now?

How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?

Morgan Stanley Upgrades Charles River Laboratories International (CRL)

Morgan Stanley Upgrades Charles River to Overweight, Raises Price Target to $220

Charles River Labs (CRL) Pulled Back Due to AI Disruption Fears

Assessing Charles River Laboratories (CRL) Valuation After Mixed Returns And Contrasting Undervaluation Signals

Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript